Kangmei Pharmaceutical Co (SHSE:600518) Additional Paid-In Capital : ¥0 Mil(As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Kangmei Pharmaceutical Co Additional Paid-In Capital?

Kangmei Pharmaceutical Co's quarterly additional paid-in capital increased from Sep. 2023 (¥0 Mil) to Dec. 2023 (¥18,748 Mil) but then stayed the same from Dec. 2023 (¥18,748 Mil) to Mar. 2024 (¥0 Mil).

Kangmei Pharmaceutical Co's annual additional paid-in capital stayed the same from Dec. 2021 (¥18,748 Mil) to Dec. 2022 (¥18,748 Mil) but then increased from Dec. 2022 (¥18,748 Mil) to Dec. 2023 (¥18,748 Mil).

Kangmei Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Kangmei Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kangmei Pharmaceutical Co Additional Paid-In Capital Chart

Kangmei Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

11,517.29

11,523.20

18,748.21

18,748.22

Kangmei Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	18,748.21	-	18,748.22	-

Kangmei Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Kangmei Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kangmei Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kangmei Pharmaceutical Co (SHSE:600518) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kangmei Pharmaceutical Co Ltd (SHSE:600518) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

N/A

Address

No. 3, Taike Road, Xiameilin, Futian District, Shenzhen, CHN, 518000

Website

http://www.kangmei.com.cn

Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the manufacturing, research and marketing of herbal medicine and chemical raw materials.

Executives

Xu Dong Jin	Director
Li Jian Hua	senior management
Qiu Xi Wei	Director
Wang Min	senior management
Peng Qin	senior management
Ma Xing Tian	Director
Lin Guo Xiong	senior management
Zhuang Yi Qing	senior management
Wen Shao Sheng	Supervisors

Kangmei Pharmaceutical Co (SHSE:600518) Headlines

No Headlines